Two consecutive quarterly profits doubled in Guizhou Lark "song" pitched

Every reporter Liu Mingtao has "Miao Medicine first stock" reputation of Guizhou Lark (002424, Close to 35.49 yuan) recently, in the Ziyun County with the Huilong cultivation farmers professional cooperatives to sign medicinal plant contract, soon after the company announced a good performance letters, 2010 to achieve net profit year-on-year growth of 44.06%, which, A net profit of $79.9654 million was recorded in the quarter, which continued to grow at a high rate. Some brokers analysis that the company's heart and brain blood-vessel drugs silver loyalty brain faster growth, new development of Chinese herbal medicine to help improve the industry chain, and combined with the seed drug integration expectations, the company's future is expected to continue to maintain high growth. High performance growth in the third quarter of last year to achieve a net profit of 36.1134 million yuan, the fourth quarter to achieve net profit of 79.9654 million Yuan, Guizhou Lark in the second half of 2010 to achieve a "great leap Forward", the annual results to 161 million yuan, up from last year's year-on-year growth of 44.06%. "Daily economic news" reporter carefully compared to find that Guizhou bailing performance really exceed the expected time point occurred in the third quarter of last year. In the third quarter of 2009, Guizhou bailing single season net profit was less than 18 million yuan, and 2010 was as high as 36.1134 million yuan, up to 109.05%. Industry insiders said that the company's three quarter quarterly performance growth, on the one hand, and the company listed after the increase in brand effect, the other is its silver loyalty brain faster growth, led to soaring performance, coupled with the market after the gradual release of capacity bottlenecks, resulting in faster growth of the company's performance. Throughout the year, the company's performance is still within expectations, the four quarter is the company's VC silver chip, such as cold medicine sales season, continue to maintain a good income. The analysis of China-created securities, Guizhou Lark 2010 years of rapid growth of the reason is mainly the company's pillar product sales growth, some products through price adjustment and control costs to achieve a steady growth, showing the company's early marketing network construction and management model reform has been successful, new product market cultivation gradually mature. Although from the performance distribution, Guizhou Lark's main product or VC silver Warpage, for the old OTC company, the market appears "interest" insufficient, but along with another main product silver loyalty brain through the rapid rise, as well as Miao medicine integration and new business development of Chinese herbal medicine, the company's future is still a bit full. Bandan the future of the broad information revealed that the silver loyalty brain Tong Soft capsule is the independent development of Guizhou Lark Pharmaceutical preparation, with invention patents, for the National health care products. Although the drug market time is relatively short, but entered the 2007, its gross profit rate rose rapidly, 2009 is the real sales income of 125 million yuan, nearly three years of compound growth of 109.32%, showing a significant rapid growth momentum. According to the company Prospectus, 2008 and 2009 Silver loyalty soft capsules in the market has been in short supply. 2008, production capacity of 199 million, the actual sales reached 235 million, production and sales rate of 118.09%; 2009 production capacity of 262 million capsules, sales of 264 million tablets, production and sales rate of 100.76%. Capacity bottlenecks have become an urgent problem to solve. After the listing of Lark in Guizhou, the use of fund-raising funds 220 million yuan to build the Tiantai Mountain Pharmaceutical GMP production line project. After the project is put into operation, the capacity of silver loyalty soft capsule will increase to 1.2 billion capsules. British Securities said that the cardiovascular drug market, the exclusive variety of opportunities, the base of silver Dan is still low. According to the state Food and Drug Administration (SFDA) statistics of the mainstream varieties of growth, the terminal sales amount in 300 million or 400 million will be slowed down, and Guizhou bailing Silver Dan 2009 years of the amount of 225 million, ample room for growth. Guizhou Lark Dong Minli in the "Daily economic news" reporter interview, said, "Silver loyalty brain soft capsule This piece, the company will definitely strengthen the future efforts to do, and our Chairman also said that before 1 billion we will grow fast." East China Sea Securities also believed that the silver loyalty soft capsule is Guizhou bailing exclusive prescription drugs, with the efficacy of the heart and brain, in the capacity bottlenecks can be resolved on the basis of this year is expected to achieve 50% growth. In addition, the company has built 70 people's Beijing Academic Promotion center, and plans to build 1000 of people's prescription drug sales force, which reflects the company's commitment to make strong prescription drugs. The cultivation of medicinal herbs is expected to be high in the field of OTC and prescription medicine to maintain high growth in Guizhou Lark, last December began to dabble in Chinese herbal medicine cultivation business. According to the company Bulletin, Guizhou Bailing's pharmaceutical sales company and Guizhou Sanyuan, Liuzhi farmers cooperatives, respectively, 10,000 mu of Pseudostellaria commissioned to plant, in addition, and Ziyun County Huilong cultivation farmers Cooperatives cooperated 10,000 mu of mountain Silver Flower commissioned planting projects. Minli told the Daily Economic news reporter, the company does have a further expansion of Chinese herbal medicine plant Business plan, but because this year is only the first of the business, the future development depends on experience and market analysis. In addition, the Guizhou Lark has begun to contact some of the seed drug acquisition project, has not yet been disclosed. Guotai analysis that the company said it is involved in the cultivation of Chinese herbal medicines to achieve self-sufficiency in raw materials, while bearing some of the local planting resources integration norms of the task, so whether to become a long-term profit model, is still difficult to determine. Pseudostellaria, which now has a bigger impact on profitability, is expected to increase the company's earnings by 0.27 yuan per share in 2011. About the mountain silver flower, the medicinal herbs as antiviral varieties, demand, price fluctuations are also large, the company has its own material needs. China Merchants Securities also said that Guizhou is one of the main areas of Chinese herbal medicine cultivation, pseudostellaria, mountain silver flower is only the beginning, the future of Guizhou Lark may be involved in more of Guizhou authentic Chinese herbal medicine planting, which will be a continuous increase in the source of profits. In addition to Chinese herbal medicine planting, the combination of Miao medicine will become a big part of the future of Guizhou Lark. Dujiang, deputy director of National Medicine Research Institute, Guizhou University of Traditional Chinese MedicineFor, if the local Miao medicine enterprises in Guizhou can break the pattern of individual combat, forming a whole brand like Tibetan medicine, Miao Medicine "Spring" is really not far. Guizhou Bailing chairman Jiang has promised that the company's 1.1 billion yuan will be all for the combination of Miao medicine. At the beginning of this year, the Guizhou Lark used its own funds to buy Guizhou Dry Yuan Pharmaceutical Co., Ltd. 100% Equity and Hebei Tak Shun Health Pharmaceutical Co., Ltd. 100% stake, which seems to herald the integration of mergers and acquisitions of the road has been opened, the results in the end, waiting for time to test.